New combo aims to revive immunotherapy in resistant cancers

NCT ID NCT06270706

Recruiting now Disease control Sponsor: Pliant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated Apr 24, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug (PLN-101095) alone and with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 124 participants will receive increasing doses to find the best dose and measure any anti-cancer effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NEXT Austin
RECRUITING

Austin, Texas, 78758, United States

Contact Email: •••••@•••••
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Email: •••••@•••••
South Texas Accelerated Research Therapeutics (START)
RECRUITING

Grand Rapids, Michigan, 49546, United States

Contact Email: •••••@•••••
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Winship Cancer Institute of Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Email: •••••@•••••
Yale University
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMOR